World Bioplastics Market to 2015

Published: November 2011
Price: $ 6100


World demand to reach $2.9 billion in 2015
World Bioplastics Market to 2015 - Global demand for biodegradable and bio-based plastics will more than triple to over one million metric tons in 2015, valued at $2.9 billion. Bioplastics have moved past the initial phase of market introduction and are now experiencing robust increases in demand in virtually all parts of the world. Gains are being fueled by a number of factors, including consumer preferences for environmentally sustainable materials, improved performance of bioplastic resins with respect to traditional plastics, and the introduction of commodity plastics produced from bio-based sources. Ultimately, however,price considerations will be the main driver of bioplastic market success, and rising petroleum costs may allow some bioplastic resins to achieve price parity with conventional plastics by the end of the decade. Starch-based resins, PLA to pace biodegradables Biodegradable plastics accounted for 90 percent of the world bioplastics market in 2010. Excellent growth is forecast for the two leading biodegradable plastics, starch-based resins and polylactic acid (PLA), both of which will more than double in demand through 2015. More rapid growth is expected for PLA, which will benefit from advancements in compounding polymerization technology, as well as its relatively low cost compared to other bioplastics. Fastest gains for biodegradable plastics, however, will be seen for polyhydroxy-alkanoate (PHA) resins, which are just beginning to enter the commercial market.

Browse All: Chemicals Market Research

Bio-based polyethylene to offer best opportunities
Despite the strong advances for biodegradable resins, non-biodegradable biobased resins will be the primary driver of bioplastics demand through 2015 and beyond. Gains will be stimulated by the availability of commercial quantities of bio-based polyethylene from Braskem’s 200,000 metric ton per year plant in Brazil, which opened in late 2010. Two other bio-based polyethylene plants, as well as bio-based polypropylene and PVC facilities, are expected to open around 2015. Additionally, industrial production of fully bio-based PET is forecast to become a reality by the end of the decade.

Asia/Pacific region to be fastest-growing market;
Brazil to become leading producer Western Europe was the leading consumer of bioplastics in 2010, as the region’s environmentally conscious consumers have been the quickest to accept biobased and biodegradable products. Starch-based resins used in biodegradable bags are particularly popular in the region. North America was another major market for bioplastics in 2010, with PLA accounting for the majority of demand. However, the fastest gains in bioplastics demand through 2015 will be seen for the Asia/Pacific region, driven by robust growth in Japan and China.Currently, world bioplastics production is heavily concentrated in the US and Western Europe. This will change dramatically by 2015, as production of  bio-based polyethylene ramps up in Brazil, making the country the world’s leading producer of bioplastics. Furthermore, China and Thailand plan to open over 100,000 metric tons of new bioplastics capacity by 2020, making these countries major players in the global market.

Study coverage
This new Freedonia industry study, World Bioplastics, is priced at $6100. It presents historical demand data (2000, 2005, 2010) and forecasts for 2015 and 2020 by product, market, world region and for 16 major countries. The study also considers market environment factors, evaluates company market share and profiles 38 industry competitors.
Company Profiles
Profiles 38 global players such as Arkema, NatureWorks, Metabolix, BASF, Innovia Films,Novamont and Rodenburg Biopolymer

US Filters Market to 2015

Published: November 2011
Price: $ 5100



US demand to exceed $12 billion in 2015
US Filters Market to 2015 - Demand for filters in the US is expected  to increase to just over $12 billion in 2015. This growth reflects an improvement over the weaker gains registered during the 2005 to 2010 period due to the economic recession that occurred during the latter half of that period. Advances will be spurred by improved manufacturing activity, and motor vehicle production
and sales, as well as strengthened environmental regulations -- particularly those involving reduced emissions from electric utilities and diesel engines, and better water quality. Additionally, heightened consumer concerns about air and water quality will boost demand for filters in the residential market.

Browse All: Environmental Market Research

Aftermarket sales to continue dominant role
Ongoing sales in the aftermarket, which accounts for the majority of demand, will also drive gains. The growing market penetration of such products as motor vehicle cabin air filters, diesel emissions filters, and home air and water filters will contribute to aftermarket demand growth. As the number of filters in operation increases and awareness among consumers of their recommended replacement schedule improves, demand for replacement filters will also increase. However, growth in the aftermarket will be offset somewhat by users’ tendency to replace filters less often than recommended by the manufacturers. The ongoing development of filters featuring longer lasting media or other technologies that extend
their useful life will also restrain sales of aftermarket filters.

Motor vehicles to remain largest market
The motor vehicle market will continue to account for the largest portion of total demand in 2015. Although the high level of price competition in this market will temper gains, advances will be aided by the large volume of these filters sold both as original equipment and in the aftermarket. Demand for filters in the industrial and manufacturing market is projected to post the fastest gains, driven by increased manufacturing activity.

Study coverage
This new Freedonia industry study, Filters, is priced at $5100. It presents historical demand data (2000, 2005 and 2010) plus forecasts for 2015 and 2020 by filter technology, product and market. The study also considers market environment factors, assesses industry structure, evaluates company market share and profiles 38 player

Personal Accident and Health Insurance in India, Key Trends and Opportunities to 2015

Published: November 2011
No. of Pages: 209
Price: $ 1950


The report provides top-level market analysis, information and insights of the Indian personal accident and health insurance industry, including:
• The Indian personal accident and health insurance industry’s growth prospects by product category and customer segment
• The various distribution channels in the Indian personal accident and health insurance industry
• The competitive landscape in the personal accident and health insurance industry
• A description of the personal accident and health reinsurance market in India

Executive Summary
The Indian personal accident and health insurance market recorded steady growth over the report’s review period, withstanding the ill effects of global economic slowdown. Growth is expected to continue, with a forecast 22% annual growth over the next five years, and a decrease in capital requirements will create an attractive market for new entrants into the market.

While public-sector insurance providers constitute the majority of the market, private participants will continue to increase their market share in the forecast period. The introduction of new distribution channels is another key factor in the growth in the overall volume of new policies.

Four public companies hold more than 50% of the market share in the personal accident and health insurance market, although this dominance will be severely challenged by private companies in the forecast period. The key entry barrier into the market is brand recognition, and companies are expected to work towards aligning with stronger brands, both domestic and foreign, to create opportunities for collaborations or joint ventures.

Scope
This report provides a comprehensive analysis of the personal accident and health insurance market in India:
• It provides historical values for India’s personal accident and health insurance industry for the report’s 2006–2010 review period and forecast figures for the 2011–2015 forecast period
• It offers a detailed analysis of the key sub-segments in India’s personal accident and health insurance industry, along with market forecasts until 2015
• It covers an exhaustive list of parameters, including written premium, incurred loss, loss ratio, commissions and expenses, combined ratio, frauds and crimes, total assets, total investment income and retentions
• It analyses the various distribution channels for personal accident and health insurance products in India
• Using Porter’s industry-standard “Five Forces” analysis, it details the competitive landscape in India for the personal accident and health insurance business
• It provides a detailed analysis of the reinsurance market in India and its growth prospects
• It profiles the top personal accident and health insurance companies in India, and outlines the key regulations affecting them.

Reasons To Buy
• Make strategic business decisions using top-level historic and forecast market data related to the Indian personal accident and health insurance industry and each sector within it
• Understand the demand-side dynamics, key market trends and growth opportunities within the Indian personal accident and health insurance industry
• Assess the competitive dynamics in the personal accident and health insurance industry, along with the reinsurance segment
• Identify the growth opportunities and industry dynamics within key product categories
• Gain insights into key regulations governing the Indian insurance industry and its impact on companies and the industry's future

Key Highlights
• The growth in the Indian personal accident and health insurance market can be attributed to increasing healthcare expenditure, economic growth, and changing demographics
• The Indian personal accident and health insurance market has a significant number of public-sector insurers. Private accident and health insurers account for less than 50% of the total accident and health insurance written premium
• During the forecast period, public-sector insurers are expected to retain a major share of the market, while the private accident and health insurers are expected to increase their market share gradually in India
• The increasing penetration of major insurance companies and banks selling insurance policies to second- and third-tier cities in India will lead to an increase in accident and health insurance policy volumes in India during the forecast period
• Key challenges include low awareness of personal accident and health insurance, low penetration in rural areas, a lack of coverage for many existing diseases, and the ineffective distribution model in the country.

Peripheral Vascular Stents - Global Pipeline Analysis, Competitive Landscape and Market Forecasts to 2017

Published: November 2011

No. of Pages: 94

Price: $ 3500

GlobalData’s new report, “Peripheral Vascular Stents - Global Pipeline Analysis, Competitive Landscape and Market Forecasts to 2017” provides key data, information and analysis on the global peripheral vascular stents market. The report provides market landscape, competitive landscape and market trends information on the peripheral vascular stents market. The report provides comprehensive information on the key trends affecting the market, and key analytical content on the market dynamics. The report also reviews the competitive landscape and technology offerings.

This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData’s team of industry experts.

Browse All: Medical Devices Market

Scope

- Key geographies covered include the US, Canada, the UK, Germany, France, Italy, Spain, Japan, China, India, Australia, and Brazil.

- Key segments covered include Fem-pop Stents, Iliac Artery Stents, Renal Stents, Carotid Artery Stents and Infrapop Stents.

- Annualized market revenues data from 2003 to 2010, forecast forward for 7 years to 2017. Company shares data for 2010.

- Qualitative analysis of key market trends, market drivers, and restraints by each category within the peripheral vascular stents market. 

- The report also covers information on the leading market players, the competitive landscape, and the leading pipeline products and technologies.

- Key players covered include Cordis Corporation, Abbott Vascular, Boston Scientific Corporation, C.R.Bard, Inc. and Covidien (ev3).

Reasons to buy

- Develop business strategies by understanding the trends and developments that are driving the peripheral vascular stents market globally.

- Design and develop your product development, marketing and sales strategies.

- Develop market-entry and market expansion strategies.

- Identify key players best positioned to take advantage of the emerging market opportunities.

- Exploit in-licensing and out-licensing opportunities by identifying products, most likely to ensure a robust return.

- What’s the next big thing in the peripheral vascular stents market landscape? – Identify, understand and capitalize.

- Make more informed business decisions from the insightful and in-depth analysis of the global peripheral vascular stents market and the factors shaping it.

Nuclear Imaging Equipment - Global Pipeline Analysis, Competitive Landscape and Market Forecasts to 2017

Published: November 2011
No. of Pages: 102
Price: $ 3500



GlobalData’s new report, “Nuclear Imaging Equipment - Global Pipeline Analysis, Competitive Landscape and Market Forecasts to 2017” provides key data, information and analysis on the global nuclear imaging equipment market. The report provides market landscape, competitive landscape and market trends information on the nuclear imaging equipment market. The report provides comprehensive information on the key trends affecting the market, and key analytical content on the market’s dynamics. The report also reviews the competitive landscape and technology offerings.

This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData’s team of industry experts.

Browse All: Medical Devices Market Research

Scope
- Key geographies covered include the US, Canada, the UK, Germany, France, Italy, Spain, Japan, China, India, Australia, and Brazil.
- Key segments covered include SPECT, SPECT/CT, PET and PET/CT Systems.
- Annualized market revenues data from 2003 to 2010, forecast forward for seven years to 2017. Company shares data for 2010.
- Qualitative analysis of key market trends, market drivers, and restraints within the nuclear imaging equipment market.
- The report also covers information on the leading market players, the competitive landscape, and the leading pipeline products and technologies.
- Key players covered include GE Healthcare, Philips Healthcare and Siemens Healthcare.

Reasons to buy
- Develop business strategies by understanding the trends and developments that are driving the nuclear imaging equipment market globally.
- Design and develop your product development, marketing and sales strategies.
- Develop market-entry and market expansion strategies.
- Identify key players best positioned to take advantage of the emerging market opportunities.
- Exploit in-licensing and out-licensing opportunities by identifying products that are most likely to ensure a robust return.
- What’s the next big thing in the nuclear imaging equipment market landscape? – Identify, understand and capitalize.
- Make more informed business decisions from the insightful and in-depth analysis of the global nuclear imaging equipment market and the factors shaping it.

Spinal Non-Fusion Devices - Global Pipeline Analysis, Opportunity Assessment and Market Forecasts to 2017

Published: November 2011
No. of Pages: 91
Price: $ 3500


GlobalData’s new report, “Spinal Non-Fusion Devices - Global Pipeline Analysis, Opportunity Assessment and Market Forecasts to 2017” provides key data, information and analysis on the global spinal non-fusion devices market. The report provides market landscape, competitive landscape and market trends information on the spinal non-fusion devices market. The report provides comprehensive information on the key trends affecting the market, and key analytical content on the market’s dynamics. The report also reviews the competitive landscape and technology offerings.

This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData’s team of industry experts.

Browse All: Medical Devices Market Research Reports 

Scope
- Key geographies covered include the US, Canada, the UK, Germany, France, Italy, Spain, Japan, China, India, Australia, and Brazil.
- Key segments covered include Artificial Disc Replacement, Dynamic Stabilization and Interspinous Process Decompression (IPD) devices.
- Annualized market revenues data from 2003 to 2010, forecast forward for seven years to 2017.
- Qualitative analysis of key market trends, market drivers, and restraints within the spinal non-fusion devices market.
- The report also covers information on the leading market players, the competitive landscape, and the leading pipeline products and technologies.
- Key players covered include Medtronic, Synthes, DePuy and Zimmer Holdings.

Reasons to buy
- Develop business strategies by understanding the trends and developments that are driving the spinal non-fusion devices market globally.
- Design and develop your product development, marketing and sales strategies.
- Develop market-entry and market expansion strategies.
- Identify key players best positioned to take advantage of the emerging market opportunities.
- Exploit in-licensing and out-licensing opportunities by identifying products that are most likely to ensure a robust return.
- What’s the next big thing in the spinal non-fusion devices market landscape? – Identify, understand and capitalize.
- Make more informed business decisions from the insightful and in-depth analysis of the global spinal non-fusion devices market and the factors shaping it.

MRI Systems - Global Pipeline Analysis, Competitive Landscape and Market Forecasts to 2017

Published: November 2011
No. of Pages: 99
Price: $ 3500

GlobalData’s new report, “MRI Systems - Global Pipeline Analysis, Competitive Landscape and Market Forecasts to 2017” provides key data, information and analysis on the global MRI systems market. The report provides market landscape, competitive landscape and market trends information on the MRI systems market. The report provides comprehensive information on the key trends affecting the market, and key analytical content on the market’s dynamics. The report also reviews the competitive landscape and technology offerings.

This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData’s team of industry experts.

Browse All:Medical Devices Market 

Scope

- Key geographies covered include the US, Canada, the UK, Germany, France, Italy, Spain, Japan, China, India, Australia, and Brazil.

- Key segments covered include High Field MRI Systems, Mid Field MRI Systems and Low Field MRI Systems.

- Annualized market revenues data from 2003 to 2010, forecast forward for seven years to 2017. Company shares data for 2010.

- Qualitative analysis of key market trends, market drivers, and restraints within the MRI systems market. 

- The report also covers information on the leading market players, the competitive landscape, and the leading pipeline products and technologies. 

- Key players covered include Siemens Healthcare, GE Healthcare, Philips Healthcare, Toshiba Medical Systems Corporation and Hitachi Medical Corporation.

Reasons to buy

- Develop business strategies by understanding the trends and developments that are driving the MRI systems market globally.

- Design and develop your product development, marketing and sales strategies.

- Develop market-entry and market expansion strategies.

- Identify key players best positioned to take advantage of the emerging market opportunities.

- Exploit in-licensing and out-licensing opportunities by identifying products that are most likely to ensure a robust return.

- What’s the next big thing in the MRI systems market landscape? – Identify, understand and capitalize.

- Make more informed business decisions from the insightful and in-depth analysis of the global MRI systems market and the factors shaping it.

X-Ray Systems - Global Pipeline Analysis, Competitive Landscape and Market Forecasts to 2017

Published: November 2011
No. of Pages: 103
Price: $ 3500

GlobalData’s new report, “X-Ray Systems - Global Pipeline Analysis, Competitive Landscape and Market Forecasts to 2017” provides key data, information and analysis on the global X-Ray systems market. The report provides market landscape, competitive landscape and market trends information on the X-Ray systems market. The report provides comprehensive information on the key trends affecting the market, and key analytical content on the market’s dynamics. The report also reviews the competitive landscape and technology offerings.

This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData’s team of industry experts.

Browse All: Medical Devices Market Research Reports

Scope

- Key geographies covered include the US, Canada, the UK, Germany, France, Italy, Spain, Japan, China, India, Australia, and Brazil.

- Key segments covered include Digital X - Ray Systems (Computed Radiography Systems and Digital Radiography Systems) and Analog X - Ray Systems.

- Annualized market revenues data from 2003 to 2010, forecast forward for seven years to 2017. Company shares data for 2010.

- Qualitative analysis of key market trends, market drivers, and restraints within the X-Ray systems market. 

- The report also covers information on the leading market players, the competitive landscape, and the leading pipeline products and technologies. 

- Key players covered include Siemens Healthcare, GE Healthcare, Philips Healthcare, Shimadzu Corporation and Toshiba Medical Systems Corporation.

Reasons to buy

- Develop business strategies by understanding the trends and developments that are driving the X-Ray systems globally.

- Design and develop your product development, marketing and sales strategies.

- Develop market-entry and market expansion strategies.

- Identify key players best positioned to take advantage of the emerging market opportunities.

- Exploit in-licensing and out-licensing opportunities by identifying products that are most likely to ensure a robust return.

- What’s the next big thing in the X-Ray systems market landscape? – Identify, understand and capitalize.

- Make more informed business decisions from the insightful and in-depth analysis of the global X-Ray systems market and the factors shaping it.

Computed Tomography Systems Market Outlook in BRICS (Brazil, Russia, India, China, South Africa) to 2017

Published: November 2011
No. of Pages: 192
Price: $ 2500

GlobalData’s new report, “Computed Tomography Systems Market Outlook in BRICS (Brazil, Russia, India, China, South Africa) to 2017” provides key market data on the Computed Tomography Systems market in the BRICS countries. The report provides value ($m), volume (units) and average price ($) data for each segment and sub-segment within three market categories –Mid Slice Computed Tomography Systems, Low Slice Computed Tomography Systems and High Slice Computed Tomography Systems. The report also provides company shares and distribution shares data for the overall Computed Tomography Systems market in each of the aforementioned countries. The report is also supplemented with global corporate-level profiles of the key market participants with information on key developments, wherever available.

This report BRICS computed tomography systems market is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData’s team of industry experts.

The emerging economies, comprising China, India, Brazil, Russia and South Africa, with a significantly large pool of under-served patients, represent the next big opportunity for the leading medical equipment and devices manufacturers. China remains the world’s most populous country and is consequently home to a large patient base. The country is home to more than 120 million people who are aged 65 or older—a population in continuous need of medical care. India, the second most populous country globally, is home to 1.2 billion people, approximately 5% of which are aged 65 or older. It’s estimated that shortly after 2020, India’s population will surpass China, making it the most populous country in the world. As the population continues to grow and people continue to age, the underlying demand for healthcare is also expected to increase.

Browse All: Medical Devices Market Research

Scope

- Market size data for Computed Tomography Systems market categories – Mid Slice Computed Tomography Systems, Low Slice Computed Tomography Systems and High Slice Computed Tomography Systems

- Annualized market revenues ($m), volume (units) and average price ($) data for each of the segments and sub-segments within the three market categories. Data from 2003 to 2010, forecast forward for seven years to 2017. 

- 2010 company shares and distribution shares data for the overall Computed Tomography Systems market in each of the aforementioned countries.

- Global corporate-level profiles of key companies operating within the Computed Tomography Systems market in BRICS.

- Key players covered include Siemens Healthcare, GE Healthcare, Toshiba Medical Systems Corporation, Philips Healthcare, and Hitachi Medical Corporation.

Reasons to buy

- Develop business strategies by identifying the key market categories and segments poised for strong growth.

- Develop market-entry and market expansion strategies.

- Design competition strategies by identifying who-stands-where in the Computed Tomography Systems competitive landscape in BRICS.

- Develop capital investment strategies by identifying the key market segments expected to register strong growth in the near future.

- What are the key distribution channels and what’s the most preferred mode of product distribution – Identify, understand and capitalize.

Healthcare IT Market Outlook in Japan to 2017 - Hospital Information Systems and Medical Imaging Information Systems

Published: November 2011
No. of Pages: 68
Price: $ 2500


GlobalData’s new report, “Healthcare IT Market Outlook in Japan to 2017 - Hospital Information Systems and Medical Imaging Information Systems” provides key market data on the Japan Healthcare IT market. The report provides value (USD million) data for each segment and sub-segment within two market categories – Hospital Information Systems and Medical Imaging Information Systems. The report also provides company shares and distribution shares data for each of the aforementioned market categories. The report is supplemented with global corporate-level profiles of the key market participants with information on company financials and pipeline products, wherever available.

This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData’s team of industry experts.

Browse All: Medical Devices Market

Scope
- Market size and company share data for Healthcare IT market categories – Hospital Information Systems and Medical Imaging Information Systems.
- Annualized market revenues (USD million) data for each of the segments and sub-segments within two market categories. Data from 2003 to 2010, forecast forward for 7 years to 2017.
- 2010 company shares and distribution shares data for each of the two market categories.
- Global corporate-level profiles of key companies operating within the Japan Healthcare ITmarket.
- Key players covered include Fujitsu Limited, FUJIFILM Holdings Corporation, Software Service, Inc., CSI Co., Ltd., NEC Corporation, GE Healthcare and others.

Reasons to buy
- Develop business strategies by identifying the key market categories and segments poised for strong growth.
- Develop market-entry and market expansion strategies.
- Design competition strategies by identifying who-stands-where in the Japan Healthcare IT competitive landscape.
- Develop capital investment strategies by identifying the key market segments expected to register strong growth in the near future.
- What are the key distribution channels and what’s the most preferred mode of product distribution – Identify, understand and capitalize.

Polycystic Ovarian Syndrome (PCOS) Therapeutics - Pipeline Assessment and Market Forecasts to 2018

Published: November 2011
No. of Pages: 78
Price: $ 3500


GlobalData, the industry analysis specialist, has released its new report, “Polycystic Ovarian Syndrome (PCOS) Therapeutics - Pipeline Assessment and Market Forecasts to 2018”. The report is an essential source of information and analysis on the global PCOS market. The report identifies the key trends shaping and driving the global PCOS market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global PCOS sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData’s team of industry experts.

GlobalData estimates that the global Polycystic Ovarian Syndrome Therapeutics market was valued at $656m in 2010, and is expected to grow at a static Compound Annual Growth Rate (CAGR) of 2.6% over the next eight years, to reach $804m by 2018. The growing treated population which is mainly due to expanding prevalence of co-morbid conditions such as diabetes, obesity and dyslipidemia will drive steady growth in PCOS therapeutics market. Although treated patients are increasing but the market is showing static growth because of the unavailability of FDA approved and presence of off-label and generic products for treatment which are having lower patient satisfaction due to lower efficacy profiles since these products can not treat all the conditions such as hyperandrogenism, infertility, hyperglycemia and hirsutism, associated with PCOS. So still a huge unmet need exists in the management of treatment pattern with the help of more efficacious products which can cure all the conditions. In the pipeline of PCOS, majority of the participants are institutions or universities. Company participation is very low because most of the drugs which are under trial are generics and already being used for this indication either alone or in combination. Therefore current pipeline products are not going to impact the market significantly.

Scope
The report provides information on the key drivers and challenges of the PCOS market. Its scope includes -
- Annualized seven key markets (US, France, Germany, Italy, Spain, UK and Japan) PCOS market revenues data from 2005 to 2010, forecast for eight years to 2018.
- Pipeline analysis data providing a split across the different phases, mechanisms of action being developed and emerging trends. Pipeline candidates fall under major therapeutic classes such as Antiplatelate action, Ovulation inducer, Hypoglycemic, Antiandrogen, Progesterone derivative, Oral contraceptives, Antiobesity drugs and others.
- Analysis of the current and future competition in the global PCOS market. Key market player covered is Reliance Life Sciences Pvt. Ltd.
- Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide a qualitative analysis of its implications.
- Key topics covered include strategic competitor assessment, market characterization, unmet needs and the implications for the PCOS therapeutic market.
- Analysis of key recent licensing and partnership agreements in PCOS market.

Reasons to buy
The report will enhance your decision making capability. It will allow you to -
- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies and by identifying the companies with the most robust pipeline.
- Develop business strategies by understanding the trends shaping and driving the global PCOS market.
- Drive revenues by understanding the key trends, innovative products and technologies, market segments and companies likely to impact the global PCOS market in future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
- What’s the next big thing in the global PCOS market landscape? – Identify, understand and capitalize.

Implantable Cardioverter Defibrillators and Cardiac Resynchronization Therapy-Defibrillators - Global Pipeline Analysis, Competitive Landscape and Market Forecasts to 2017

Published: November 2011
No. of Pages: 89
Price: $ 3500

GlobalData’s new report, “Implantable Cardioverter Defibrillators and Cardiac Resynchronization Therapy-Defibrillators - Global Pipeline Analysis, Competitive Landscape and Market Forecasts to 2017” provides key data, information and analysis on the global implantable cardioverter defibrillators and cardiac resynchronization therapy defibrillators market. The report provides market landscape, competitive landscape and market trends information on the implantable cardioverter defibrillators market and cardiac resynchronization therapy defibrillators market. The report provides comprehensive information on the key trends affecting the market, and key analytical content on the market dynamics. The report also reviews the competitive landscape and technology offerings.

This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData’s team of industry experts.

Browse All: Medical Devices Market Research Reports

Scope

- Key geographies covered include the US, Canada, the UK, Germany, France, Italy, Spain, Japan, China, India, Australia, and Brazil.

- Key segments covered include Cardiac Resynchronisation Therapy - Defibrillators, Dual Chamber Implantable Cardioverter Defibrillators and Single Chamber Implantable Cardioverter Defibrillators.

- Annualized market revenues data from 2003 to 2010, forecast forward for 7 years to 2017. Company shares data for 2010.

- Qualitative analysis of key market trends, market drivers, and restraints by each category within the implantable cardioverter defibrillators and cardiac resynchronization therapy defibrillators market. 

- The report also covers information on the leading market players, the competitive landscape, and the leading pipeline products and technologies. 

- Key players covered include Medtronic, Boston Scientific, St. Jude Medical, BIOTRONIK and Sorin Group.

Reasons to buy

- Develop business strategies by understanding the trends and developments that are driving the implantable cardioverter defibrillators and cardiac resynchronization therapy defibrillators market globally.

- Design and develop your product development, marketing and sales strategies.

- Develop market-entry and market expansion strategies.

- Identify key players best positioned to take advantage of the emerging market opportunities.

- Exploit in-licensing and out-licensing opportunities by identifying products, most likely to ensure a robust return.

- What’s the next big thing in the implantable cardioverter defibrillators and cardiac resynchronization therapy defibrillators market landscape? – Identify, understand and capitalize.

- Make more informed business decisions from the insightful and in-depth analysis of the global implantable cardioverter defibrillators and cardiac resynchronization therapy defibrillators market and the factors shaping it.

Nuclear Energy Quarterly Deals Analysis - M&A and Investment Trends, Q3 2011

Published: November 2011

No. of Pages: 36

Price: $ 1500

GlobalData’s “Nuclear Energy Quarterly Deals Analysis - M&A and Investment Trends, Q3 2011” report is an essential source of data and trend analysis on Mergers and Acquisitions (M&As) and financings in the nuclear energy market. The report provides detailed information on M&As, equity and debt offerings, private equity and venture capital (PE/VC) and partnership transactions recorded in the nuclear energy industry in Q3 2011. The report provides detailed comparative data on the number of deals and their value in the last five quarters, categorized by deal types, segments and geographies. The report also provides information on the top advisory firms in the nuclear energy industry.

Data presented in this report is derived from GlobalData’s proprietary in-house Nuclear Energy eTrack deals database and primary and secondary research.

Scope

- Analyze market trends for the nuclear energy market in the global arena

- Review of deal trends in uranium mining & processing, equipment and services, and power generation markets

- Analysis of M&A, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships in the nuclear energy industry

- Summary of Nuclear energy deals Q3 2011 globally in the last five quarters

- Information on top deals happened in the nuclear energy industry

- Geographies covered include – North America, Europe, Asia Pacific, South & Central America, and Middle East & Africa

- League Tables of financial advisors in M&A and equity/debt offerings. This includes key advisors such as Morgan Stanley, Credit Suisse, and Goldman Sachs

Reasons to buy

- Enhance your decision making capability in a more rapid and time sensitive manner

- Find out the major deal performing segments for investments in your industry

- Evaluate type of companies divesting / acquiring and ways to raise capital in the market

- Do deals with an understanding of how competitors are financed, and the mergers and partnerships that have shaped the nuclear energy market

- Identify major private equity/venture capital firms that are providing finance in the nuclear energy market

- Identify growth segments and opportunities in each region within the industry

- Look for key financial advisors where you are planning to raise capital from the market or for acquisitions within the industry

- Identify top deals makers in the nuclear energy market

Additional Information

M&As Decreased In The Nuclear Energy Market In Q3 2011

M&As and asset transactions, which include changes in the ownership and control of companies or assets (GlobalData does not consider this value as a new investment in the market), in the nuclear energy industry registered a significant decrease of 84% in deal value with $1.3 billion in Q3 2011, as compared to $8.2 billion in Q2 2011. The significant difference in deal value was due to the high value deal of Exelon’s agreement to merge with Constellation Energy Group for $7.9 billion in Q2 2011. However, excluding this deal, the industry recorded an increase in deal value from $0.3m in Q2 2011 to $1.3 billion in Q3 2011. The number of M&A deals increased from six in Q2 2011 to 10 deals in Q3 2011. North America remained dominant in the nuclear energy M&A activity with seven deals in Q3 2011, followed by Europe with two deals.

According to Prabhanjan, Analyst at GlobalData, “Post Japan nuclear crisis, most of the utility companies continue to focus on reviewing their safety standards at the existing and under construction nuclear power reactors. Barring the high value deal of Exelon’s agreement to merge with Constellation Energy Group for $7.9 billion in Q2 2011 there were no significant M&A deals. The industry recorded a mere increase in deal value from $0.3m in Q2 2011 to $1.3 billion in Q3 2011. However this stance of utility companies in the industry may not sustain for long period, because the growing energy needs and the government’s commitment to cut down carbon emission rates will induce companies to move from cautionary mode to action mode.”

New Investments In The Nuclear Energy Industry Decreased In Q3 2011

Investments in nuclear energy companies, including new investments through equity/debt offerings and financings by PE/VC firms, recorded a decrease of 23% in the number of deals and 59% in deal value with 73 delas worth $9 billion in Q3 2011, as compared to 95 deals worth $21.9 billion in Q2 2011.

Equity offerings accounted for 70% of the total financing deals with 51 deals in Q3 2011, and in terms of capital raised, debt offerings accounted for 98% of the deal value with $8.8 billion in Q3 2011.

North America topped the table with 31 deals worth $5.2 billion in Q3 2011, followed by Asia-Pacific with 37 deals worth $1.4 billion in Q3 2011. Schneider Electric’s proposed offering of Euro medium term notes for $1.1 billion, China Guangdong Nuclear Power’s private placement of notes for $783.7m, and ABB’s public offering of notes for $566m were some of the notable deals registered in Q3 2011.

According to Prabhanjan, Analyst at GlobalData, “The new investments in nuclear energy industry has decreased in Q3 2011 by 23% in the number of deals and 59% by value with 73 delas worth $9 billion in Q3 2011, as compared to 95 deals worth $21.9 billion in Q2 2011. This trend emphasizes the fact that the nuclear accident in Japan is not only having an affect on the country’s future nuclear power projects but also on the global nuclear power industry. Germany has decided to close its nuclear power plants by 2022 and focus on alternate energy production. The US is intending to revisit their safety measures and emergency preparation strategy pertaining to the nuclear power reactors in the country. However Asia-Pacific countries such as India and China are planning to strengthen their safety measures for operating nuclear power reactors and continue their nuclear power project plans.”

Decreased Financing Through Equity Offerings and Debt Offerings In Q3 2011

Global equity offerings, including initial public offerings (IPOs), secondary offerings, and private investment in public equities (PIPEs), registered a significant decrease of 96% in deal value from $4.1 billion in Q2 2011 to $147.3m in Q3 2011. The large difference was due to PPL Corporation’s two separate secondary offerings of $2.3 billion and $977.5m in Q2 2011. The average deal value also registered a substantial decrease from $63m in Q2 2011 to $2.9m in Q2 2011. The number of deals registered a decrease of 23% from 66 in Q2 2011 to 51 in Q3 2011. PIPE segment accounted for 75% of the total number of deals, with 38 deals in Q3 2011. Secondary offerings accounted for 42% of the total investments, with $62.4m in Q3 2011.

Global debt offerings, including public and private debt placements, by nuclear energy companies registered a decrease of 12% in the number of deals and 40% in deal value with 22 deals worth $8.8 billion in Q3 2011, as compared to 25 deals worth $14.8 billion in Q2 2011. Public debt offerings registered a marginal decrease in deal value from $8 billion in Q2 2011 to $7.5 billion in Q3 2011, while private debt placements registered a substantial decrease of 85% in deal value from $6.8 billion in Q2 2011 to $1.3 billion in Q3 2011.

Deals Decreased In North America And Europe In Q3 2011

North America and Europe recorded a decrease of 8% and 46% in the number of deals with 54 and seven deals in Q3 2011, as compared to 59 and 13 deals respectively in Q2 2011. Deal values in both the regions also decreased substantially from $21 billion and $8.2 billion in Q2 2011 to $5.3 billion and $3.5 billion respectively in Q3 2011. Exelon’s agreement to merge with Constellation Energy Group, valued at $7.9 billion, PPL Corporation’s three separate public offerings with a combined worth of $4.6 billion, Energy Future Holdings’s private placement of 11.5% senior secured notes for $1.7 billion, and NRG Energy’s private placement of senior notes for $1.2 billion were the major transactions that led to a high deal value in Q2 2011. Some of the high value deals in Europe, which led to a high deal value in Q2 2011, include Qatar Holdings’s acquisition of 6.16% stake in Iberdrola for $2.7 billion, Ansaldo Electric Drives’s acquisition of 45% interest in Ansaldo Energia for $1.7 billion, and Enel’s private placement of bonds for $1.4 billion.

The Asia Pacific region registered an increase in the number of deals and deal value with 43 deals worth $1.4 billion in Q3 2011, as compared to 40 deals worth $645.6m in Q2 2011. Australia continued to dominate the nuclear market in the Asia-Pacific region, accounting for 93% of the number of deals with 40 deals in Q3 2011. The increase in deal activity in Australia was primarily driven by the expected increase in demand for uranium resources as nuclear power programs are on the rise. The number of deals in China decreased from two nuclear deals in Q2 2011 to one deal in Q3 2011.

According to Prabhanjan, Analyst at GlobalData, “The governments across the different nations are taking necessary precautionary steps to strengthen the safety measures of their respective nuclear power plants post Japan Nuclear crisis. Countries such as India, China, Russian Federation and South Korea are moving forward with their nuclear power plans while European countries have either decided to either close or slow down their nuclear plans. The government’s commitment to reduce greenhouse gas emissions and adhere to Kyoto protocol has made them to include nuclear in their country’s energy mix. The necessity to rely on nuclear may be one of the primary reasons for them to provide loan guarantees for new nuclear projects. Due to loan guarantees already the need for the utility companies to finance through equity and debt offerings declined. The Japan’s nuclear crisis further decreased the financing through equity and debt offerings.”

Fibromyalgia Therapeutics - Pipeline Assessment and Market Forecasts to 2018

Published: November 2011
No. of Pages: 83
Price: $ 3500

GlobalData, the industry analysis specialist, has released its new report, “Fibromyalgia Therapeutics - Pipeline Assessment and Market Forecasts to 2018”. The report is an essential source of information and analysis on the global FM market. The report identifies the key trends shaping and driving the global FM market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global FM sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData’s team of industry experts.

The global market for Fibromyalgia (FM) was valued at $1.7 billion in 2010 and is expected to grow at a Compound Annual Growth Rate (CAGR) of 4.3% to reach $2.4 billion by 2018. The restricted growth in the market is due to the unavailability of approved drugs in the EU and Japan market, expected patent expiry of Cymbalta (2013) and Lyrica (2018) and lack of newer therapies in late stage FM therapeutics pipeline. Currently, FDA (Food and Drug Administration) has approved three drugs for the treatment of FM. Lyrica (pregabalin) was the first drug approved in June 2007 followed by Cymbalta (duloxetine) in June 2008 and Savella (milnacipran) in January 2009. Marketing authorization of these drugs has been rejected by EMEA (European Medical Agency) due low effectiveness and high adverse reactions associated with the drugs. Cymbalta was the first drug to be rejected by EMEA in 2008, followed by Lyrica in 2009 and Savella in 2010. However, increasing prevalence and diagnosis is expected to drive the future FM therapeutic market.

Scope

The report provides information on the key drivers and challenges of the FM market. Its scope includes - 

- Annualized global FM market revenues data from 2005 to 2010, forecast for eight years to 2018. 

- Pipeline analysis data providing a split across the different phases, mechanisms of action being developed and emerging trends. Pipeline candidates fall under major therapeutic classes such as therapies based on SSRI and GABA agonist calcium channel blocker, sodium channel blocker, nonrepinephrine reuptake inhibitor, NMDA antagonist.

- Analysis of the current and future competition in the global FM market. Key market players covered are the Pfizer, Jazz Pharmaceuticals and UCB.

- Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide a qualitative analysis of its implications. 

- Key topics covered include strategic competitor assessment, market characterization, unmet needs and the implications for the FM therapeutics market.

Reasons to buy

The report will enhance your decision making capability. It will allow you to - 

- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies and by identifying the companies with the most robust pipeline. 

- Develop business strategies by understanding the trends shaping and driving the global FM market. 

- Drive revenues by understanding the key trends, innovative products and technologies, market segments and companies likely to impact the global FM market in future. 

- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors. 

- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage. 

- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships. 

- What’s the next big thing in the global FM market landscape? – Identify, understand and capitalize.

GPCRs in Drug Discovery - Efforts to De-Orphanize Novel GPCR Targets are Increasing

Published: November 2011
No. of Pages: 143
Price: $ 3500

A superfamily of diverse transmembrane receptors, GPCRs help in the activation of cellular responses by interacting with molecules outside the cell. These molecules are known as ligands. The cellular responses are activated through a system of signaling pathways, called as signal transduction pathways. Human genome sequencing has helped us to understand the importance of these diverse classes of receptors, with about 1,000 sequences identified to be GPCRs. About 400 GPCRs bind with endogenous ligands; however such ligands have not been discovered for about 33% of all GPCR targets, thus emphasizing on the potential these receptors have as targets for future drug discovery.

Novel Research Methods are Being Employed to Identify and Develop Products that Target GPCRs More Effectively

The understanding of GPCR biology was limited for a very long time, although researchers were successful in identifying many GPCR targets using genomic approaches. However, there was no real understanding of the receptor structure-function relationship, and how different signaling molecules activated these receptors. Hence, the goal was to find the endogenous and/or exogenous ligands that paired with each GPCR, which could help the discovery of new avenues in therapy and de-orphanization of GPCRs. However, there are still more than 100 orphan GPCRs for which ligands have not yet been identified. This coupled with the fact that only about 30% of the 800 odd GPCRs have been targeted so far by currently marketed medicines leads to the conclusion that GPCR research has immense potential to bring out new therapies. Basic research advances concerning receptor X-ray structures, allosteric interactions and functional selectivity have opened the way for further exploitation of this large and diverse class of targets.

Research and Development Efforts in the Area of GPCRs will be Concentrated, Especially on De-Orphanization of Orphan GPCRs

Some of the new GPCRs discovered, especially those discovered through sequence homology, had one basic problem in that the endogenous ligands that bind to these receptors could not be identified. Hence, such receptors without any endogenous ligands were termed orphan GPCRs. One would think that functional activity of orphan GPCRs would be questioned as there are no known ligands that bind to these receptors, however expression of these orphan receptors in many different species accounts for their functional activity. Discovery of ligands that target orphan GPCRs is proving to be an extremely challenging task for researchers and for pharmaceutical and biotechnology companies all over the world. With the number of new molecules that get approval from the regulatory authorities falling drastically, coupled with the arrival of a patent cliff for the next four to five years, researchers are looking at the super-family of GPCRs with more interest than ever before. One of the most important segments of GPCR research concentrates on de-orphanizing GPCRs, identifying unknown ligands and establishing functional activity for orphan receptors.

Pipeline Analysis of Molecules Reveals the Central Nervous System, Oncology and Cardiovascular System to be the Most Targeted Therapeutic Classes

There are many programs looking at the role of GPCRs in obesity, the role of GPCRs in pain states, and in controlling tumorigenesis. A large number of CNS diseases involve GPCRs, ranging from depression to neurodegenerative diseases such as Alzheimer's disease, and they are therefore looked at in both the peripheral and the central nervous system. Many research papers defining receptor pharmacology use the brain for ligand-binding experiments. Modern research labs continue to study receptor pharmacology in brain tissue. There may be a preponderance of work on GPCRs in CNS because of this history, but there are lots of opportunities to progress GPCR therapeutics in many other areas.

Report overview

This report GPCRs in Drug Discovery - Efforts to De-Orphanize Novel GPCR Targets are Increasing provides insights in to the technical and commercial importance of G protein coupled receptors, which are the most important category of receptors in the human body. The report provides a scientific understanding of GPCRs and details the novel research methods being employed in the research of new targets and molecules that can be more effective in treating many indications. A special note on Orphan GPCRs and ways to de-orphanize them is followed by a detailed pipeline analysis to understand the therapeutic classes and indications that are being targeted through GPCRs. The report provides an in-depth analysis of the competitive landscape, including the profiling of top companies and licensing agreements involving GPCR molecules and platform technologies.

Browse All: Pharmaceuticals Market Research

Scope

The scope of this report includes -

• Detailed technical understanding of G protein coupled receptors

• Dedicated sections on Novel research methods being used to improve the GPCR targeted drug discovery and development process

• Understanding of Orphan GPCRs, its importance and novel methods to locate ligands and de-orphanize these receptors

• Pipeline analysis of products at various stages of development targeting receptors classified as GPCRs, including identification of major therapeutic areas and indications

• Analysis and review of important strategic partnerships and licensing agreements in the area of GPCR drug discovery and development

• The report also covers information on the leading market players and the competitive landscape, including specialist companies which have proprietary GPCR platform technology as well as major companies with molecules in not only the NDA Filed stage but also in Phase III

Reasons to buy

The report GPCRs in Drug Discovery will enhance your decision making capability. It will allow you to -

• Develop business strategies by understanding the trends shaping and driving research in the field of GPCRs

• Understand the potential areas of application for GPCR therapies.

• Identify key molecules targeting GPCRs in development based on the therapy.

• Identify the key players investing in GPCR platform technologies

• Optimize your R&D pipeline through identification of novel technologies being used in GPCR research to improve the drug discovery process

• Identify emerging players with a potentially strong product portfolio of molecules targeting GPCRs and create effective counter-strategies to gain a competitive advantage.

• What's the next big thing in GPCR research? – Identify, understand and capitalize.

Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics - Pipeline Assessment and Market Forecasts to 2018

Published: November 2011
No. of Pages: 126
Price: $ 3500

GlobalData, the industry analysis specialist, has released its new report, “Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics - Pipeline Assessment and Market Forecasts to 2018”. The report is an essential source of information and analysis on the global ADHD market. The report identifies the key trends shaping and driving the global ADHD market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global ADHD sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData’s team of industry experts.

GlobalData estimates that the global ADHD therapeutics market was valued at $3855.6m in 2010, and is forecast to grow at a compound annual growth rate (CAGR) of 8.0% over the next eight years, to reach $7114.5m by 2018. Between 2005 and 2010, three drugs namely Daytrana (methylphenidate), Vyvanse (lisdexamfetamine) and Intuniv (guanfacine) were approved in the US. The acceptance for Vyvanse was high in the US, in spite of its high treatment cost in comparison to that of existing drugs. Thus, high acceptance for Vyvanse has resulted in the significant growth of the market. In 2009, the authorized generic versions of Adderall XR (mixed amphetamine salt) were launched, due to which the US market declined. This has resulted in the decline in the global ADHD market in 2009.

Between 2010 and 2018, the global ADHD market is expected to grow at a CAGR of 8%. The growth rate is similar across the US and European countries, but it is slightly high in Japan (18.4%). This difference across geographical markets exists because of the variation in the approval date for some of the drugs in the US, Europe and Japan. In the US, major nonstimulant therapies such as Vyvanse, Intuniv and Kapvay (clonidine hydrochloride) are already approved; whereas these drugs are not approved in Europe and Japan. The entry of Vyvanse and Intuniv in major European markets is expected in 2012 and 2014 respectively. Vyvanse, being a safer nonstimulant, its acceptance across Europe would be high and considered as growth driving factor for the European ADHD market. The other drugs which are expected to enter into the market during the forecast period such as NWP06, CM4612 and RIT124D have similar therapeutic mode of action as that of exiting drugs which will not impact the market significantly.

During this forecast period, patents for various drugs such as Adderall XR, Daytrana, Concerta (methylphenidate), Strattera (atomoxetine) and Kapvay are set to expire. However, the losses due to expiry of these patents would be compensated by new drugs entering the market such as Vyvanse and Intuniv. Thus, the global ADHD market will show a steady growth from 2010 to 2018.

Scope
The report provides information on the key drivers and challenges of the ADHD market. Its scope includes -
- Annualized seven key markets (US, France, Germany, Italy, Spain, UK and Japan) ADHD market revenues data from 2005 to 2010, forecast for eight years to 2018.
- Pipeline analysis data providing a split across the different phases, mechanisms of action being developed and emerging trends. Pipeline candidates fall under major therapeutic classes such as norepinephrine-dopamine reuptake inhibitor, selective alpha2A-adrenergic receptor agonist, serotonin-norepinephrine-dopamine reuptake inhibitor, selective serotonin (5-HT1)-dopamine antagonist, serotonin (5-HT1A and 5-HT1B) receptor agonists, highly selective norepinephrine reuptake inhibitor (NRI), antagonist of alcohol-metabolic effects, dopamine partial agonist, alpha 4 beta 2 neuronal nicotinic receptor (NNR) agonists, dopamine antagonist, alpha7 NNR agonist., serotonin and norepinephrine reuptake inhibitor, selective serotonin reuptake inhibitors (SSRIs), dopamine (D2) receptors and serotonin type 2 (5-HT2) receptor agonist, alpha 3 beta 2 and alpha 4 beta 2 NNR antagonist, histamine H3 receptor antagonist, selective alpha2A-adrenergic receptor agonist, histamine H3 autoreceptor antagonist, α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) glutamate receptor modulators, specific phosphodiesterase 1 (PDE1) inhibitor, dopamine uptake inhibitors and serotonin (5-HT6) receptor antagonist.
- Analysis of the current and future competition in the global ADHD market. Key market players covered are Curemark LLC, Johnson & Johnson, Nextwave Pharmaceuticals, Novartis AG and Shire Plc.
- Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide a qualitative analysis of its implications.
- Key topics covered include strategic competitor assessment, market characterization, unmet needs and the implications for the ADHD therapeutics market.
- Analysis of key recent licensing and partnership agreements in ADHD market.

Reasons to buy
The report will enhance your decision making capability. It will allow you to -
- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies and by identifying the companies with the most robust pipeline.
- Develop business strategies by understanding the trends shaping and driving the global ADHD market.
- Drive revenues by understanding the key trends, innovative products and technologies, market segments and companies likely to impact the global ADHD market in future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
- What’s the next big thing in the global ADHD market landscape? – Identify, understand and capitalize.

Osteoporosis Therapeutics - Pipeline Assessment and Market Forecasts to 2018

Published: November 2011
No. of Pages: 147
Price: $ 3500

GlobalData, the industry analysis specialist, has released its new report, “Osteoporosis Therapeutics - Pipeline Assessment and Market Forecasts to 2018”. The report is an essential source of information and analysis on the global osteoporosis therapeutics market. The report identifies the key trends shaping and driving the global osteoporosis therapeutics market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global osteoporosis therapeutics sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData’s team of industry experts.

GlobalData analysis shows that the global osteoporosis therapeutics market stood at $6.9 billion in 2005 and grew at a Compound Annual Growth Rate (CAGR) of 4.5% to reach $8.5 billion in 2010. GlobalData forecasts that the global osteoporosis therapeutics market will grow moderately at a CAGR of 3.3% over the next eight years to reach $11.1 billion by 2018. The current competitive landscape consists mainly of bisphosphonates, selective estrogen receptor modulators (SERM), receptor activator of nuclear factor kappa-B (RANK) ligand (RANKL) inhibitor drugs and hormone therapy, which includes parathyroid hormone apart from estrogen and progesterone. The recent launch of Prolia (denosumab), a monoclonal antibody from the therapeutic class RANKL inhibitor, has also opened new avenues for the treatment of osteoporosis with improved safety, efficacy and compliance to medication by the patient. The bisphosphonates are the preferred drug for treatment and are used as the first line of therapy for the treatment of osteoporosis. The expected moderate growth can be attributed to the increase in awareness among people regarding osteoporosis, especially among females about postmenopausal osteoporosis (PMO) which contributes the largest number of patient pool to osteoporosis. GlobalData also predicts that an increase in the patient population as a consequence of the ageing population will drive the moderate growth in the osteoporosis therapeutics market. The modest growth observed in the osteoporosis therapeutics market during 2010 to 2018 can also be attributed to the expected launch of pipeline products such as Odanacatib (MK 0822), NB S101 during the late forecast period. The patent expiry of Actonel (risedronate sodium), Boniva (ibandronate), Reclast (zoledronic acid), Evista (raloxifene) and Protelos (strontium malonate) during 2012 to 2014 will act as the major barriers for the growth of osteoporosis therapeutics market during the forecast period. The impending patent expiry of Boniva in 2012; Actonel and Reclast in 2013; and Evista in 2014 means patients will have access to treatment at much lower prices reflecting brand erosion of these drugs. The sales growth will also be affected by Fosamax (alendronate) generics, which lost its patent exclusivity in 2008. The main treatment options available in the osteoporosis therapeutics market include alendronate, Reclast, Actonel, Boniva, Evista, Prolia, Forteo (teriparatide), Miacalcin (calcitonin salmon), Prempro (estrogen) and Premarin (conjugated estrogens and medroxyprogesterone acetate) among others.

Scope

The report provides information on the key drivers and challenges of the osteoporosis therapeutics market. Its scope includes - 

- Annualized seven key markets (the US, France, Germany, Italy, Spain, the UK and Japan) osteoporosis therapeutics market revenues data from 2005 to 2010, forecast for eight years to 2018. 

- Pipeline analysis data providing a split across the different phases, mechanisms of action being developed and emerging trends by seven key markets. Pipeline candidates fall under major therapeutic classes such as osteoclast activity inhibitors, osteoclast activity promoters, bone anabolic agents, SERMs, SARMs, RANKL inhibitors, dual acting bone agents, PTH release stimulator, cathepsin K inhibitor, bone morphogenetic protein signaler, aminobisphosphonate, DKK1 Protein inhibitor and osteoblast level promotor

- Analysis of the current and future competition in the seven key countries osteoporosis therapeutics market. Key market players covered are Amgen, Merck, Novartis, Pfizer, Osteologix, EffRx, Zydus, Astellas and Radius.

- Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide a qualitative analysis of its implications. 

- Key topics covered include strategic competitor assessment, market characterization, unmet needs and the implications for the osteoporosis therapeutics therapeutics market.

- Analysis of key recent licensing and partnership agreements in osteoporosis therapeutics market

Reasons to buy

The report will enhance your decision making capability. It will allow you to - 

- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies and by identifying the companies with the most robust pipeline. 

- Develop business strategies by understanding the trends shaping and driving the global osteoporosis therapeutics market. 

- Drive revenues by understanding the key trends, innovative products and technologies, market segments and companies likely to impact the global osteoporosis therapeutics market in future. 

- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors. 

- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage. 

- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships. 

- What’s the next big thing in the global osteoporosis therapeutics market landscape? – Identify, understand and capitalize.

Osteoarthritis Therapeutics - Pipeline Assessment and Market Forecasts to 2018

Published: November 2011

No. of Pages: 105

Price: $ 3500

 GlobalData, the industry analysis specialist, has released its new report, “Osteoarthritis Therapeutics - Pipeline Assessment and Market Forecasts to 2018”. The report is an essential source of information and analysis on the global osteoarthritis therapeutics market. The report identifies the key trends shaping and driving the global osteoarthritis therapeutics market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global osteoarthritis therapeutics sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData’s team of industry experts.

GlobalData estimates that the global OA therapeutics market was worth $4.4 billion in 2010 and forecasts it to grow at a compound annual growth rate (CAGR) of 3.8% to reach $5.9 billion by 2018. The current treatment options for OA offer only symptomatic relief and are primarily dominated by generics. There are no disease modifying osteoarthritis drugs (DMOAD) currently approved in the OA therapeutics market and the late stage pipeline also lacks DMOADs except SMC021. Owing to all the above factors the OA therapeutics market is expected to show slow growth till 2018.

Scope

The report provides information on the key drivers and challenges of the osteoarthritis therapeutics market. Its scope includes - 

- Annualized seven key markets (US, France, Germany, Italy, Spain, UK and Japan) osteoarthritis therapeutics market revenues data from 2005 to 2010, forecast for eight years to 2018. 

- Pipeline analysis data providing analysis of the different phases of development, mechanisms of action and emerging trends. Pipeline candidates for osteoarthritis fall under major therapeutic classes such as stem cell therapy, cyclooxygenase (COX) inhibitor, cathepsin inhibitors, opioid receptor agonist, anti-nerve growth factor (NGF) inhibitor, transient receptor potential vanilloid-1 (TRPV-1) antagonists, cyclooxygenase inhibiting nitric oxide donor, phosphodiesterase inhibitor and calcitonin receptor agonist.

- Analysis of current and future competition in the global osteoarthritis market is provided. Key market players covered are BioDelivery Sciences International, Cephalon Inc, Iroko Pharmaceuticals,LLC, Novartis AG, SantoSolve AS and Winston Pharmaceuticals, Inc.

- Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide a qualitative analysis of its implications. 

- Key topics covered include strategic competitor assessment, market characterization, unmet needs and the implications for the osteoarthritis therapeutics market.

- Analysis of key recent licensing and partnership agreements in osteoarthritis therapeutics market.

Reasons to buy

The report will enhance your decision making capability. It will allow you to - 

- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies and by identifying the companies with the most robust pipeline. 

- Develop business strategies by understanding the trends shaping and driving the global osteoarthritis therapeutics market. 

- Drive revenues by understanding the key trends, innovative products and technologies, market segments and companies likely to impact the global osteoarthritis therapeutics market in future. 

- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors. 

- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.

- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships. 

- What’s the next big thing in the global osteoarthritis therapeutics market landscape? – Identify, understand and capitalize.

Growth Hormone Deficiency (GHD) Therapeutics - Pipeline Assessment and Market Forecasts to 2018

Published: November 2011
No. of Pages: 98
Price: $ 3500


GlobalData, the Industry analysis specialist, has released its new report, “Growth Hormone Deficiency (GHD) Therapeutics - Pipeline Assessment and Market Forecasts to 2018”. The report is an essential source of information on the global growth hormone deficiency therapeutics market, and provides analysis of a number of key areas. The report identifies the key trends shaping and driving the global growth hormone deficiency therapeutics market and provides insights into the current competitive landscape and emerging companies expected to significantly alter the market positioning of current market leaders. Most importantly, the report provides valuable insights into the pipeline products within the global growth hormone deficiency sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData’s team of industry experts.

GlobalData estimates that the global GHD therapeutics market values $1,354.5m in 2010, after increasing at a Compound Annual Growth Rate (CAGR) of 4.0% during 2005–2010. However, the market is expected to record a CAGR of 3.7% from 2010–2018, to value $1,804.7m by 2018. The growth recorded in GHD therapeutics market during 2005-2010, was primarily attributed to increase in the annual cost of therapy with the existing treatment options available. Apart from this, there are limited numbers of biosimilars formulation such as Omnitrope (somatropin), Valtropin (somatropin) in GHD therapeutics market. The launches of biosimilars have modest impact on the GHD therapeutics market because of availability of these products present at a competitive price. The Omnitrope was approved by the US Food and Drug Administration (US FDA) after long delays and court proceedings.

Scope
The report provides information on the key drivers and challenges of the growth hormone deficiency therapeutics market. Its scope includes -
- Annualized seven key markets (the US, France, Germany, Italy, Spain, the UK and Japan) growth hormone deficiency therapeutics market revenue data for 2005–2010, and 2011–2018.
- Pipeline analysis data providing a split across the different phases, mechanisms of action being developed and emerging trends by seven key markets. Pipeline candidate’s fall under the therapy classes such as immunomodulator, anti-CD3 antibody, oral Insulin analogue, GLP-1 receptor agonist, interleukin-1 inhibitor, ultra-long acting insulin analogue, ultra-fast-acting insulin analogue, Insulin analogue and ultra rapid-acting insulin analogue.
- Analysis of the current and future competition in the seven key countries of the growth hormone deficiency therapeutics market. LG Life Sciences, BioPartners GmbH, Roche Group, Pfizer, Novo Nordisk, Astrazeneca, Ascendis Pharma A/S, Ipsen S.A., EMD Serono, Inc., Theratechnologies Inc, Eli Lilly and Company and Ambrx, Inc.they are key market players, is covered in this section.
- Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide a qualitative analysis of its implications.
- Key topics covered include strategic competitor assessment, market characterization, unmet needs and the implications for the growth hormone deficiency therapeutics market.
- Analysis of key recent licensing and partnership agreements in growth hormone deficiency therapeutics market.

Reasons to buy
The report will enhance your decision making capability. It will allow you to -
- Develop and design in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
- Develop business strategies by understanding the trends shaping and driving the global growth hormone deficiency therapeutics market.
- Increase revenue through an understanding of the key trends, innovative products and technologies, market segments and companies likely to affect the global growth hormone deficiency therapeutics market in the future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and analyzing the performance of various competitors.
- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
- Organize sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
- What’s the next big thing in the global growth hormone deficiency therapeutics market landscape? – Identify, understand and capitalize.

Heart Failure (HF) Therapeutics - Pipeline Assessment and Market Forecasts to 2018

Published: November 2011
No. of Pages: 105
Price: $ 3500


GlobalData, the Industry analysis specialist, has released its new report, “Heart Failure (HF) Therapeutics - Pipeline Assessment and Market Forecasts to 2018”. The report is an essential source of information on the global Heart Failure therapeutics market, and provides analysis of a number of key areas. The report identifies the key trends shaping and driving the global Heart Failure therapeutics market and provides insights into the current competitive landscape and emerging companies expected to significantly alter the market positioning of current market leaders. Most importantly, the report provides valuable insights into the pipeline products within the global Heart Failure sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData’s team of industry experts.

The global Heart Failure (HF) therapeutics market valued at $3,269.0m in 2005, and grew at a Compound Annual Growth Rate (CAGR) of 4.5% to reach $4,068.5m in 2010. GlobalData analysis suggests that the global HF therapeutics market will grow at a high CAGR of 2.5% over the next eight years, to reach $5,104.1m by 2018. This growth will be primarily attributed due to the expected launch of novel, therapies relaxin and LCZ696 during the forecast period. Relaxin is expected to be launched in late 2014 and LCZ696 in 2015. An increase in the treatment seeking population due to an increase in the life expectancy and increasing awareness leading to diagnosis at an early stage will also drive the HF therapeutics market. Apart from these the HF therapeutics market will be driven by the increases in aging population which are more susceptible towards Acute Heart Failure (AHF). The current competition in the HF therapeutics market is weak, primarily dominated by generic drugs such as milirinone, dobutamine, digoxin, Coreg (carvedilol), and Altace (ramipril). Only Diavon (valsartan) and Natrecor (nesiritide) are the two branded product which are expected to lose patents in 2012 and 2014 respectively.

Browse All: Pharmaceuticals Market

Scope
The report provides information on the key drivers and challenges of the Heart Failure therapeutics market. Its scope includes -
- Annualized seven key markets (the US, France, Germany, Italy, Spain, the UK and Japan) Heart Failure therapeutics market revenue data for 2005–2010, and 2011–2018.
- The late stage pipeline has molecules which would affect progression of HF, known as renin inhibitor, Angiotensin receptor neprilysin (ANRI) inhibitor and vasodilators in acute case of heart failure. The other promising drugs in the HF developmental pipeline in terms of mechanism of action include a stem cell therapy, angiotensin converting enzyme inhibitor, aldosterone antagonist, natriuretic peptide receptor agonist, and glucagon-like peptide 1 agonist.
- Analysis of the current and future competition in the key countries of the Heart Failure therapeutics market. Novartis, Amgen, Cardiokline, Bayer, Nile Therapeutics, Cytokinetics, and GlaxoSmithKline are the key players, they are key market players, is covered in this section.
- Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide a qualitative analysis of its implications.
- Key topics covered include strategic competitor assessment, market characterization, unmet needs and the implications for the Heart Failure therapeutics market.
- Analysis of key recent licensing and partnership agreements in Heart Failure therapeutics market.

Reasons to buy
The report will enhance your decision making capability. It will allow you to -
- Develop and design in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
- Develop business strategies by understanding the trends shaping and driving the global Heart Failure therapeutics market.
- Increase revenue through an understanding of the key trends, innovative products and technologies, market segments and companies likely to affect the global Heart Failure therapeutics market in the future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and analyzing the performance of various competitors.
- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
- Organize sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
- What’s the next big thing in the global Heart Failure therapeutics market landscape? – Identify, understand and capitalize.